It should be noted that, in the phase III double-blind comparative study, abnormal ejaculation (e.g., retrograde ejaculation) was reported in 39 (22.3%) of 175 patients.
Clinically significant adverse reactions: Syncope, unconsciousness (Incidence unknown): Since a transient unconsciousness associated with hypotension etc. may occur, patients should be carefully monitored and, in the event of any abnormalities, treatment with UROTEX should be discontinued and appropriate therapeutic action taken.
Impaired hepatic function, jaundice (Both incidence unknown): Impaired hepatic function associated with increased AST (GOT), increased ALT (GPT) etc. or jaundice may occur, patients should be carefully monitored and, in the event of any abnormalities, appropriate measures, such as discontinuation of UROTEX should be taken.
Other adverse reactions: The following adverse reactions may occur. Therefore, if any abnormalities are observed, appropriate therapeutic measures such as dosage reduction or discontinuation of treatment should be taken. (See Table 8.)
Click on icon to see table/diagram/image
View ADR Reporting Link
Sign Out